Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Candel Therapeutics Inc (NASDAQ: CADL) closed at $5.58 in the last session, up 1.64% from day before closing price of $5.49. In other words, the price has increased by $1.64 from its previous closing price. On the day, 0.91 million shares were traded. CADL stock price reached its highest trading level at $5.8 during the session, while it also had its lowest trading level at $5.39.
Ratios:
We take a closer look at CADL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.04 and its Current Ratio is at 7.04. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On September 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 306314656 and an Enterprise Value of 213968656.
Stock Price History:
The Beta on a monthly basis for CADL is -0.93, which has changed by 0.056818128 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 2.33%, while the 200-Day Moving Average is calculated to be -9.71%.
Shares Statistics:
According to the various share statistics, CADL traded on average about 749.99K shares per day over the past 3-months and 653230 shares per day over the past 10 days. A total of 54.89M shares are outstanding, with a floating share count of 37.81M. Insiders hold about 31.12% of the company’s shares, while institutions hold 37.57% stake in the company. Shares short for CADL as of 1760486400 were 7473390 with a Short Ratio of 9.96, compared to 1757894400 on 7434796. Therefore, it implies a Short% of Shares Outstanding of 7473390 and a Short% of Float of 17.19.
Earnings Estimates
Candel Therapeutics Inc (CADL) is presently subject to a detailed evaluation by 2 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.23 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.77 and -$0.77 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.46, with 1.0 analysts recommending between -$0.46 and -$0.46.
